Concepedia

Publication | Open Access

A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma

DOIFull Paper Access

64

Citations

18

References

2019

Year

Sumanta K. Pal, Andres Forero‐Torres, John A. Thompson, John C. Morris, Saurabh Chhabra, Christopher Hoimes, Nicholas J. Vogelzang, Thomas E. Boyd, Paulo Gustavo Bergerot, Jacob J. Adashek,
Cancer

Abstract

The modest antitumor activity of SGN-CD70A does not support its development in mRCC. However, given the high disease control rate in a heavily pretreated population and the modest toxicity profile, CD70 remains of interest because of its immunomodulatory properties.

References

YearCitations

Page 1